MYCODAPT ™-S

DESCRIPTION
Mycodapt™-S (Mycophenolate Sodium delayed release tablet) is a prescription medicine given to prevent rejection in people who have received a kidney transplant. Rejection is when the kidney recipient’s immune system senses the transplanted kidney(organ) as “foreign” and attacks it. Mycodapt™-S is usually given to kidney transplant recipients along with other immunosuppressants like Cyclosporine or Tacrolimus and corticosteroids. There are numerous papers published on the usage of Mycophenolate in many other ailments like Lupus and Nephrotic Syndrome either alone or in combination of other medication. However, its such usage is totally dependent on the expertise and experience of the treating health care practitioner.
PRESENTATION
Alu-alu Foil pack of 10 delayed release tablets of Mycodapt™-S in one strip and six strips in a box.
COMPOSITION
Mycodapt™-S : Each delayed release tablet contains Mycophenolate Sodium 360 mg.
INDICATION
Mycodapt™-S is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in paediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.
DOSAGE
Mycodapt™-S (Mycophenolate Sodium tablets) should be taken empty stomach , at least one hour before meal or two hours after meal. Since it is delayed release tablet, Mycodapt™-S should not be crushed or broken and has to be taken completely.
Dosage in Adult Kidney Transplant Patients:
The recommended dose of Mycodapt™-S is 720 mg administered twice daily (1440 mg total daily dose).
Dosage in Paediatric Kidney Transplant Patients:
The recommended dose of Mycodapt™-S in conversion (at least 6 months post-transplant) in paediatric patients age 5 years and older is 400 mg/m^2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily)
BENEFITS OF Mycodapt™-S
Mycodapt™-S, enteric coated Mycophenolate Sodium delayed release tablets offer GI tolerability to patients who may encounter such episodes post kidney transplant. Many studies have endorsed the usage of Mycophenolate sodium in successful management of immunosuppression in combination with other medicines in kidney transplant recipients.